Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
Rhea-AI Summary
Adial Pharmaceuticals (NASDAQ: ADIL) announced that CEO Cary Claiborne was a featured guest on The Big Biz Show. The episode aired on October 15, 2025 on cable networks including Fox Business, NBCUniversal and Time Warner Cable, on streaming services such as Roku, Apple TV and fire TV, and on radio via The Biz Talk Radio Network, Armed Forces Radio and iHeart Media reaching 175 countries.
The program is also available on the company website at www.adial.com/newsroom.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ADIL declined 3.36%, reflecting a moderate negative market reaction. This price movement removed approximately $283K from the company's valuation, bringing the market cap to $8M at that time.
Data tracked by StockTitan Argus on the day of publication.
GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial, was invited to appear as a featured guest on the Big Biz Show, an Emmy Award-winning nationally syndicated radio and TV program.
The show aired on Wednesday, October 15, 2025, and aired on cable TV on Fox Business, NBCUniversal, and Time Warner Cable, and streaming services, including Roku, Apple TV, fire TV, as well as on radio via The Biz Talk Radio Network, Armed Forces Radio and iHeart Media in 175 countries. Additionally, the show is available on the Company’s website here: www.adial.com/newsroom.
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
Forward-Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: adil@crescendo-ir.com
FAQ
When did Cary Claiborne, CEO of Adial (NASDAQ: ADIL), appear on The Big Biz Show?
Which networks and platforms broadcast the Adial CEO interview on October 15, 2025?
How can investors watch the Adial CEO's Big Biz Show appearance?
Did the Big Biz Show appearance on October 15, 2025 include clinical data about ADIL therapies?
Will the Big Biz Show appearance immediately affect Adial (ADIL) stock price?
In how many countries was the Adial CEO segment distributed on radio and streaming on October 15, 2025?
